Abstract
Objectives: Radiofrequency ablation (RFA) has gained acceptance for thoracic surgery use but few data exist regarding its value in thoracic oncology. The aim of this study is to report our experience RFA for malignant lung tumors.
Methods: From 2010 27 patientes were underwent RFA for peripheral malignant tumors: metastases (n 20), primary lung cancer (n 7). Rrange of theres dimensions were from 7 to 52 mm (mean 27 mm.). Renal cell carcinoma metastases had 4 patientes, metastases of colorectal carcinoma - 10, metastases of lung cancer - 5 and hepatocelular carcinoma - 1. Indications for RFA: inabity undergo thoracotomy (9), us alternative complition pneumonectomy after lung resections (4), necessity to save lung tissue for patients with multiple lung metastases (14). We used transcutaneus RFA in 7 cases. In 14 cases thoracoscopic detection of tumor node before RFA was used. In 6 cases RFA used during thoracotomy. Used needle electrode with test portion 30 mm., maximal power and exposition of 10 min. Mediana follow-up was 19 month (2-32).
Results: No postoperative mortality. Post-operative complications were associated with pulmonury tissue inflammation (6 cases). Average hospital stay of uncomplicated patients was 3-7 days. At present no local recurrences were diagnosed. But 7 patients developed new pulmonury and hepatic metastases from 3 to 18 months after RFA and 9 patientes died from progression of oncological diseases from 6 to 26 month after RFA. Four patients have died from concomitant diseases from 1.5 and to 5 month after RFA. The median survival was 19.5 month (1.5- 30).
Conclusion: RFA is a reasonable option if a lesion is unresectable or necessity tissue sparing for multiple lung resection.
- © 2011 ERS